Author:
Furniss Frederick,Biswas Asit B.
Publisher
Springer International Publishing
Reference219 articles.
1. Adler, B. A., Wink, L. K., Early, M., Shaffer, R., Minshawi, N., McDougle, C. J., & Erickson, C. A. (2015). Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study. Autism, 19(1), 102–106.
https://doi.org/10.1177/1362361314524641
2. Aman, M. G., Arnold, L. E., & Armstrong, S. C. (1999). Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5(4), 279–289.
https://doi.org/10.1002/(SICI)1098-2779(1999)5:4<279::AID-MRDD5>3.0.CO;2-6
3. Aman, M., Buitelaar, J., De Smedt, G., Wapenaar, R., & Binder, C. (2005). Pharmacotherapy of disruptive behavior and item changes on a standardized rating scale: Pooled analysis of risperidone effects in children with subaverage IQ. Journal of Child and Adolescent Psychopharmacology, 15(2), 220–232.
https://doi.org/10.1089/cap.2005.15.220
4. Aman, M. G., Burrow, W. H., & Wolford, P. L. (1995). The Aberrant Behavior Checklist-community: Factor validity and effect of subject variables for adults in group homes. American Journal on Mental Retardation, 100(3), 283–292.
5. Aman, M. G., De Smedt, G., Derivan, A., Lyons, B., Findling, R. L., Hagerman, R., … Swanson, J. (2002). Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. American Journal of Psychiatry, 159(8), 1337–1346.
https://doi.org/10.1176/appi.ajp.159.8.1337